Profile data is unavailable for this security.
About the company
Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Company’s portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.
- Revenue in GBP (TTM)--
- Net income in GBP--
- Incorporated2020
- Employees--
- LocationRoquefort Therapeutics PLC85 Great Portland Street,, First FloorLONDON W1W 7LTUnited KingdomGBR
- Phone+44 20 3918 8633
- Websitehttps://www.roquefortplc.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Seed Innovations Ltd | -1.28m | -2.09m |
| Wildcat Petroleum PLC | 0.00 | 15.00k |
| Oneiro Energy PLC | 13.28k | -390.18k |
| British & American Investment Trust Plc | -1.19m | -2.32m |
| Vox Valor Capital Ltd | 4.39m | -147.62k |
| Bay Capital PLC | 0.00 | -1.31m |
| APQ Global Ltd | 6.34m | -5.39m |
| Sure Ventures PLC | -208.43k | -638.49k |
| Roquefort Therapeutics PLC | -100.00bn | -100.00bn |
| Africa Opportunity Fund Limited | 0.00 | -1.33m |
| Investment Company PLC (THE) | 413.97k | 104.58k |
| Oxford Technology 2 Ventr Cptl Trst PLC | -1.62m | -1.81m |
| Guinness VCT PLC | -100.00bn | -100.00bn |
| Bowen Fintech PLC | -100.00bn | -100.00bn |
| Reabold Resources PLC | 0.00 | -979.00k |
